Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD

Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study

(2019) Joseph Biederman et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial

(2019) Robert L. Findling et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

(2019) Janet K. Johnson et al.   Journal of Attention Disorders

A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)

(2018) Tim L. Wigal et al.   CNS DRUGS

Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling

(2018) Josephine Elia et al.   Nature Communications

Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents

(2013) Samuele Cortese et al.   JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY

Reinforcement, Dopamine and Rodent Models in Drug Development for ADHD

(2012) Gail Tripp et al.   Neurotherapeutics